{"id":131179,"date":"2018-08-02T14:38:38","date_gmt":"2018-08-02T18:38:38","guid":{"rendered":"https:\/\/www.countingpips.com\/?p=131179"},"modified":"2018-08-02T07:39:09","modified_gmt":"2018-08-02T11:39:09","slug":"biotech-releases-white-paper-on-alzheimers-disease-candidate","status":"publish","type":"post","link":"https:\/\/www.investmacro.com\/forex\/2018\/08\/biotech-releases-white-paper-on-alzheimers-disease-candidate\/","title":{"rendered":"Biotech Releases White Paper on Alzheimer’s Disease Candidate"},"content":{"rendered":"
August 2, 2018<\/div>
\r\n<\/div><\/div>

By The Life Science Report<\/b><\/p>\n

Source: Streetwise Reports<\/em> \u00a0\u00a008\/01\/2018<\/a><\/b><\/p>\n

A company focused on treatment of neurodegenerative diseases has issued a white paper discussing its lead candidate.<\/p><\/blockquote>\n

ProMIS Neurosciences Inc. (PMN:TSX; ARFXF:OTCQB)<\/a> has issued a white paper in association with its participation in the 2018 Alzheimer’s Association International Conference (AAIC), according to a July 31 press release<\/a>. The company made a poster presentation at the conference regarding its lead candidate, humanized PMN310, which it says “shows unrivaled selectivity for native toxic A\u03b2O derived from human AD brains, with no off-target binding to A\u03b2 monomers or plaque.”<\/p>\n

At the AAIC, one area of focus was “the causative role of amyloid-beta oligomers (A\u03b2O) in the development and progression of Alzheimer’s disease (AD) and the importance of neutralizing A\u03b2O toxicity represented a common theme across multiple oral presentations and posters,” the company stated.<\/p>\n

The ProMIS white paper, titled “State of the Art at AAIC 2018<\/a>,” addresses that theme, exploring the idea that “targeting toxic amyloid-beta oligomers offers renewed hope for treatment of Alzheimer’s disease.”<\/p>\n

“We believe the oligomer selectivity of PMN310 supports a potential best in class product profile compared to other therapeutic antibodies currently showing promising results in clinical trials,” ProMIS President and CEO Dr. Elliot Goldstein stated.<\/p>

\r\n
\r\n

Free Reports:<\/p><\/div>\r\n

\r\n

<\/a>\r\n\t Get Our Free Metatrader 4 Indicators<\/u><\/b><\/a> - Put Our Free MetaTrader 4 Custom Indicators on your charts when you join our Weekly Newsletter<\/p>

\r\n
\r\n
\r\n

<\/a>\r\n\t Get our Weekly Commitment of Traders Reports<\/u><\/b><\/a> - See where the biggest traders (Hedge Funds and Commercial Hedgers) are positioned in the futures markets on a weekly basis.<\/p>

\r\n<\/div>\r\n

\r\n
<\/div>\n

Humanized PMN310 “is on track to enter Phase 1 clinical testing in the second half of 2019 and will include biomarker assessment as an integral part of the study design,” according to the company.<\/p>\n

\n

Read what other experts are saying about:<\/p>\n